INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36701, 2033, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36702, 2034, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36703, 2035, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36704, 2038, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36705, 2426, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36706, 4281, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36707, 7813, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36708, 7814, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36709, 8768, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36710, 8769, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36711, 11228, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36712, 11232, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36713, 11234, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36714, 11236, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36715, 11237, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36716, 11512, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36717, 15804, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36718, 15805, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36719, 18431, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36720, 18432, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36721, 22416, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36722, 23465, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36723, 23476, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36724, 23477, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36725, 27980, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36726, 27981, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36727, 28279, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36728, 28280, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36729, 28282, 'Carbamazepine', 'Thyroid Diseases', 'Decreased values for thyroid function tests have been observed with carbamazepine administration.  One study reported decreased serum levels of T4, FT4, and T3.  In that study, TSH concentrations were not significantly altered.  Clinicians should be cognizant of these effects when prescribing or administering carbamazepine therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36730, 0, 'Cemiplimab', 'Hepatic Insufficiency', 'Cemiplimab has not been studied in patients with moderate or severe hepatic impairment.  Caution and close monitoring is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36731, 0, 'Cemiplimab', 'Kidney Diseases', 'Immune-mediated nephritis and renal dysfunction has been reported in patients receiving treatment with cemiplimab.  Nephritis led to permanent discontinuation of treatment in some cases.  Systemic corticosteroids were required in all patients with nephritis.  Monitor patients with history of renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36732, 2294, 'Cefprozil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36733, 2295, 'Cefprozil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36734, 2297, 'Cefprozil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36735, 2298, 'Cefprozil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36736, 2300, 'Cefprozil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36737, 27382, 'Cefprozil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36738, 29914, 'Cefprozil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36739, 29915, 'Cefprozil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36740, 29916, 'Cefprozil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36741, 2294, 'Cefprozil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36742, 2295, 'Cefprozil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36743, 2297, 'Cefprozil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36744, 2298, 'Cefprozil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36745, 2300, 'Cefprozil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36746, 27382, 'Cefprozil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36747, 29914, 'Cefprozil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36748, 29915, 'Cefprozil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36749, 29916, 'Cefprozil', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36750, 2294, 'Cefprozil', 'Phenylketonurias', 'Cefzil (brand of cefprozil) oral suspension contains 28 mg of phenylalanine per each 5 mL of reconstituted suspension for both the 125 mg/5 mL and 250 mg/5mL strengths.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36751, 2295, 'Cefprozil', 'Phenylketonurias', 'Cefzil (brand of cefprozil) oral suspension contains 28 mg of phenylalanine per each 5 mL of reconstituted suspension for both the 125 mg/5 mL and 250 mg/5mL strengths.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36752, 2297, 'Cefprozil', 'Phenylketonurias', 'Cefzil (brand of cefprozil) oral suspension contains 28 mg of phenylalanine per each 5 mL of reconstituted suspension for both the 125 mg/5 mL and 250 mg/5mL strengths.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36753, 2298, 'Cefprozil', 'Phenylketonurias', 'Cefzil (brand of cefprozil) oral suspension contains 28 mg of phenylalanine per each 5 mL of reconstituted suspension for both the 125 mg/5 mL and 250 mg/5mL strengths.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36754, 2300, 'Cefprozil', 'Phenylketonurias', 'Cefzil (brand of cefprozil) oral suspension contains 28 mg of phenylalanine per each 5 mL of reconstituted suspension for both the 125 mg/5 mL and 250 mg/5mL strengths.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36755, 27382, 'Cefprozil', 'Phenylketonurias', 'Cefzil (brand of cefprozil) oral suspension contains 28 mg of phenylalanine per each 5 mL of reconstituted suspension for both the 125 mg/5 mL and 250 mg/5mL strengths.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36756, 29914, 'Cefprozil', 'Phenylketonurias', 'Cefzil (brand of cefprozil) oral suspension contains 28 mg of phenylalanine per each 5 mL of reconstituted suspension for both the 125 mg/5 mL and 250 mg/5mL strengths.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36757, 29915, 'Cefprozil', 'Phenylketonurias', 'Cefzil (brand of cefprozil) oral suspension contains 28 mg of phenylalanine per each 5 mL of reconstituted suspension for both the 125 mg/5 mL and 250 mg/5mL strengths.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36758, 29916, 'Cefprozil', 'Phenylketonurias', 'Cefzil (brand of cefprozil) oral suspension contains 28 mg of phenylalanine per each 5 mL of reconstituted suspension for both the 125 mg/5 mL and 250 mg/5mL strengths.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36759, 2294, 'Cefprozil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36760, 2295, 'Cefprozil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36761, 2297, 'Cefprozil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36762, 2298, 'Cefprozil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36763, 2300, 'Cefprozil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36764, 27382, 'Cefprozil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36765, 29914, 'Cefprozil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36766, 29915, 'Cefprozil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36767, 29916, 'Cefprozil', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36768, 2294, 'Cefprozil', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36769, 2295, 'Cefprozil', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36770, 2297, 'Cefprozil', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36771, 2298, 'Cefprozil', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36772, 2300, 'Cefprozil', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36773, 27382, 'Cefprozil', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36774, 29914, 'Cefprozil', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36775, 29915, 'Cefprozil', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36776, 29916, 'Cefprozil', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36777, 2294, 'Cefprozil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36778, 2295, 'Cefprozil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36779, 2297, 'Cefprozil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36780, 2298, 'Cefprozil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36781, 2300, 'Cefprozil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36782, 27382, 'Cefprozil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36783, 29914, 'Cefprozil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36784, 29915, 'Cefprozil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36785, 29916, 'Cefprozil', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36786, 16030, 'Cefpodoxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36787, 16031, 'Cefpodoxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36788, 16032, 'Cefpodoxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36789, 16055, 'Cefpodoxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36790, 16135, 'Cefpodoxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36791, 17873, 'Cefpodoxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36792, 22405, 'Cefpodoxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36793, 24243, 'Cefpodoxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36794, 24244, 'Cefpodoxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36795, 25018, 'Cefpodoxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36796, 25019, 'Cefpodoxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36797, 25020, 'Cefpodoxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36798, 25021, 'Cefpodoxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36799, 27381, 'Cefpodoxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (36800, 28143, 'Cefpodoxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
